Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 10, 2009, Pages 4807-4813

  Nomoto, Hiroyuki ^a,b   Shiraga, Fumio ^a   Kuno, Noriyuki ^c   Kimura, Erika ^c   Fujii, Shinobu ^c   Shinomiya, Katsuhiko ^c   Nugent, Alex K ^b   Hirooka, Kazuyuki ^a   Baba, Tetsuya ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EYE DROPS; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHOROID; CILIARY BODY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; IRIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RETINA; SINGLE DRUG DOSE; ANIMAL; BIOAVAILABILITY; CONJUNCTIVA; DRUG ANTAGONISM; INJECTION; RABBIT; TISSUE DISTRIBUTION; TOPICAL DRUG ADMINISTRATION; VITREOUS BODY;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; CONJUNCTIVA; DRUG ADMINISTRATION ROUTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; INJECTIONS; RABBITS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 68349106079     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3148     Document Type: Article

References (57)

1. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular agerelated macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249-256.
2. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in agerelated macular degeneration: results of the Pan-American Collaborative Retina Study group at 12 months follow-up. Retina. 2008; 28:1387-1394.
3. Avila MP, Farah ME, Santos A, Duprat JP, Woodward BW, Nau J. Twelve-month short-term safety and visual acuity results from a multicentre, prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol. 2008;93:305-309.
4. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705.
5. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125:1363-1366.
6. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008;246:837-842.
7. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28:1053-1060.
8. Arevalo JF, Sanchez JG, Fromow-Guerra J, et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):735-43.
9. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141-149.
10. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular edema secondary to retinal vein occlusion: twelve-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93(4):452-456.
11. Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114:1574-1579.
12. Ziemssen F, Deuter CM, Stuebiger N, Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol. 2007;245: 917-918.
13. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26: 352-354.
14. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115:1571-1580.
15. Mennel S, Callizo J, Schmidt JC, Meyer CH. Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections. Acta Ophthalmol Scand. 2007; 85:689-691.
16. Charbel Issa P, Finger RP, Holz FG, Scholl HP. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol. 2008;92:941-945.
17. Yoon YH, Kim JG, Chung H, Lee SY. Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab. Acta Ophthalmol. Published online August 13, 2008.
18. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246: 1379-1381.
19. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114: 855-859.
20. Heiduschka P, Julien S, Hofmeister S, Bartz-Schmidt KU, Schraermeyer U. Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina. 2008;28:46-55.
21. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-269.
22. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814-2823.
23. Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye. Br J Ophthalmol. 2008;92:541-544.
24. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993.
25. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147.
26. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;33:23-28.
27. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245: 1577-1579.
28. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:33-38.
29. Bock F, Konig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008;246:281-284.
30. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27:70-73.
31. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos- Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-431.
32. Kim TI, Kim SW, Kim S, Kim T, Kim EK. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea. 2008;27:349-352.
33. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-1755; 1755 e1751.
34. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-512.
35. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7:335-345.
36. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556-560.
37. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686.
38. Robinson MR, Lee SS, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82:479-487.
39. Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 2006;58:1164-1181.
40. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci. 2008;49:320-332.
41. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185.
42. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.
43. Maurice DM, Polgar J. Diffusion across the sclera. Exp Eye Res. 1977;25:577-582.
44. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the choroid-Bruch's layer. Invest Ophthalmol Vis Sci. 2006;47:4513-4522.
45. Dunlevy JR, Rada JA. Interaction of lumican with aggrecan in the aging human sclera. Invest Ophthalmol Vis Sci. 2004;45:3849-3856.
46. Vlckova M, Kalman F, Schwarz MA. Pharmaceutical applications of isoelectric focusing on microchip with imaged UV detection. J Chromatogr A. 2008;1181:145-152.
47. Raviola G. Conjunctival and episcleral blood vessels are permeable to blood-borne horseradish peroxidase. Invest Ophthalmol Vis Sci. 1983;24:725-736.
48. Wani MA, Haynes LD, Kim J, et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A. 2006;103:5084-5089.
49. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994;372: 379-383.
50. Kim H, Fariss RN, Zhang C, Robinson SB, Thill M, Csaky KG. Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci. 2008;49:2025-2029.
51. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645-2668.
52. Brereton HM, Taylor SD, Farrall A, et al. Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br J Ophthalmol. 2005;89:1205-1209.
53. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
54. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-87.
55. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86:372-376.
56. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
57. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol. 2004;22:1198.